CoChat

Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis

Open access
Lee, Bei Shi, Hards, Kiel, Engelhart, Curtis A, Hasenoehrl, Erik J, Kalia, Nitin P, Mackenzie, Jared S, Sviriaeva, Ekaterina, Chong, Shi Min Sherilyn, Manimekalai, Malathy Sony S, Koh, Vanessa H, Chan, John, Xu, Jiayong, Alonso, Sylvie, Miller, Marvin J, Steyn, Adrie J C, Grüber, Gerhard, Schnappinger, Dirk, Berney, Michael, Cook, Gregory M, Moraski, Garrett C, Pethe, Kevin · 2021 · EMBO Molecular Medicine
Cited by 97

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

The approval of bedaquiline has placed energy metabolism in the limelight as an attractive target space for tuberculosis antibiotic development. While bedaquiline inhibits the mycobacterial F 1 F 0 ATP synthase, small molecules targeting other components of the oxidative phosphorylation pathway have been identified. Of particular interest is Telacebec (Q203), a phase 2 drug candidate inhibitor of the cytochrome bcc:aa 3 terminal oxidase. A functional redundancy between the cytochrome bcc:aa 3 and the cytochrome bd oxidase protects M . tuberculosis from Q203‐induced death, highlighting the attractiveness of the bd ‐type terminal oxidase for drug development. Here, we employed a facile whole‐cell screen approach to identify the cytochrome bd inhibitor ND‐011992. Although ND‐011992 is ineffective on its own, it inhibits respiration and ATP homeostasis in combination with Q203. The drug combination was bactericidal against replicating and antibiotic‐tolerant, non‐replicating mycobacteria, and increased efficacy relative to that of a single drug in a mouse model. These findings suggest that a cytochrome bd oxidase inhibitor will add value to a drug combination targeting oxidative phosphorylation for tuberculosis treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202013207

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 97

Metadata

Authors
Lee, B. S., Hards, K., Engelhart, C. A., Hasenoehrl, E. J., Kalia, N. P., Mackenzie, J. S., Sviriaeva, E., Chong, S. M. S., Manimekalai, M. S. S., Koh, V. H., Chan, J., Xu, J., Alonso, S., Miller, M. J., Steyn, A. J. C., Grüber, G., Schnappinger, D., Berney, M., Cook, G. M., Moraski, G. C., & Pethe, K.
Venue
EMBO Molecular Medicine
Published
2020-12-07
Volume
13
Issue
1
Pages
e13207-e13207
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3112736433
Cited by
97
References
13
FWCI
1.36
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis. https://app.cochat.ai/papers/10.15252/emmm.202013207
The paper
Lee, B. S., Hards, K., Engelhart, C. A., Hasenoehrl, E. J., Kalia, N. P., Mackenzie, J. S., Sviriaeva, E., Chong, S. M. S., Manimekalai, M. S. S., Koh, V. H., Chan, J., Xu, J., Alonso, S., Miller, M. J., Steyn, A. J. C., Grüber, G., Schnappinger, D., Berney, M., Cook, G. M., . . . Pethe, K. (2021). Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202013207

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.